ERBB2 and breast carcinoma: In breast cancer, the transmembrane MUC1‐C‐terminal subunit (MUC1‐C) interacts with EGFR, ErbB2, and other receptor tyrosine kinases and contributes to the activation of the PI3K→AKT and MEK→ERK pathways.61